Quantbot Technologies LP Buys Shares of 50,089 Tempus AI, Inc. $TEM

Quantbot Technologies LP purchased a new stake in shares of Tempus AI, Inc. (NASDAQ:TEM) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 50,089 shares of the company’s stock, valued at approximately $4,043,000.

Several other hedge funds and other institutional investors have also made changes to their positions in TEM. Cranbrook Wealth Management LLC acquired a new stake in Tempus AI in the 3rd quarter valued at approximately $25,000. GAMMA Investing LLC acquired a new position in Tempus AI during the 3rd quarter worth $28,000. Allworth Financial LP boosted its position in Tempus AI by 5,000.0% during the 2nd quarter. Allworth Financial LP now owns 459 shares of the company’s stock worth $29,000 after acquiring an additional 450 shares during the period. SouthState Corp grew its stake in shares of Tempus AI by 3,761.5% in the second quarter. SouthState Corp now owns 502 shares of the company’s stock worth $32,000 after purchasing an additional 489 shares in the last quarter. Finally, Tsfg LLC increased its holdings in shares of Tempus AI by 1,515.2% during the third quarter. Tsfg LLC now owns 533 shares of the company’s stock valued at $43,000 after purchasing an additional 500 shares during the period. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Tempus AI

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Beat-and-raise fundamentals — Tempus reported robust Q4 and full‑year 2025 results (strong revenue growth, narrower net loss, positive adjusted EBITDA progression) and issued 2026 guidance that targets revenue growth and a first full‑year adjusted EBITDA inflection, supporting a fundamental recovery case. Why Tempus AI (TEM) Is Down 7.5% After 2025 Results
• Positive Sentiment: Product & commercial catalysts — Launch of an HRD‑RNA oncology algorithm and a partnership with Median Technologies to expand lung cancer screening distribution broaden Tempus’s diagnostic pipeline and addressable market if adoption scales. Tempus AI Deepens Precision Oncology Role With New HRD And Lung Tools
• Positive Sentiment: Institutional support and rebound narrative — Several outlets highlight heavy institutional buying, improving unit economics and analyst upside scenarios, which could limit downside and set up a technical rebound if execution continues. Tempus AI Sold Off After a Beat—But the Rebound Case Is Building
• Neutral Sentiment: Investor event calendar — Management will present at the Morgan Stanley TMT conference (March 3); the fireside chat could provide additional color but is not a guaranteed catalyst. Tempus to Participate in the Morgan Stanley Technology, Media & Telecom Conference
• Neutral Sentiment: Valuation updates — Some fair‑value and price‑target revisions trimmed upside modestly; analysts still show a range of bullish and cautious views, leaving the story sensitive to near‑term execution. How The Tempus AI (TEM) Investment Story Is Evolving With New Data And Valuation Views
• Negative Sentiment: Analyst downgrades and price‑target cuts — Recent analyst actions (including a notable downgrade reported 2/27 and several target cuts in the prior 24 hours) have intensified selling pressure and weakened sentiment despite the beat. Tempus AI (NASDAQ:TEM) Shares Down 7.4% After Analyst Downgrade
• Negative Sentiment: ESOP shelf registration and dilution risk — Tempus filed a US$343.38M ESOP‑related shelf registration; potential future share issuance tied to employee plans can pressure the stock if investors fear dilution. Why Tempus AI (TEM) Is Down 7.5% After 2025 Results
• Negative Sentiment: Execution, debt and market risk — High leverage, a volatile post‑IPO trading history, elevated beta and lingering execution/valuation concerns make the stock susceptible to outsized moves on negative headlines. Is It Time To Reassess Tempus AI (TEM) After Recent Share Price Weakness?

Tempus AI Stock Performance

Shares of TEM opened at $53.25 on Monday. The company has a debt-to-equity ratio of 2.52, a current ratio of 3.13 and a quick ratio of 3.00. The firm’s 50 day moving average is $61.34 and its 200-day moving average is $73.35. Tempus AI, Inc. has a 12-month low of $36.22 and a 12-month high of $104.32. The stock has a market capitalization of $9.47 billion, a P/E ratio of -37.77 and a beta of 5.29.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Needham & Company LLC cut their price objective on shares of Tempus AI from $100.00 to $75.00 and set a “buy” rating on the stock in a research note on Wednesday, February 25th. Stifel Nicolaus set a $60.00 price target on shares of Tempus AI in a research report on Wednesday. Wall Street Zen lowered shares of Tempus AI from a “hold” rating to a “sell” rating in a research note on Saturday. JPMorgan Chase & Co. decreased their price objective on shares of Tempus AI from $80.00 to $60.00 and set a “neutral” rating for the company in a report on Wednesday, February 25th. Finally, HC Wainwright lowered their price objective on shares of Tempus AI from $98.00 to $89.00 and set a “buy” rating on the stock in a research note on Friday, November 7th. Eight research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $79.31.

Insider Transactions at Tempus AI

In other news, CFO James William Rogers sold 19,966 shares of the firm’s stock in a transaction on Thursday, December 11th. The stock was sold at an average price of $73.20, for a total transaction of $1,461,511.20. Following the completion of the sale, the chief financial officer directly owned 111,250 shares of the company’s stock, valued at $8,143,500. This trade represents a 15.22% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Erik Phelps sold 9,464 shares of the business’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $59.43, for a total value of $562,445.52. Following the sale, the executive vice president directly owned 79,816 shares in the company, valued at $4,743,464.88. This trade represents a 10.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 590,109 shares of company stock valued at $37,056,566 in the last 90 days. 26.27% of the stock is owned by corporate insiders.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.